Cervical Cancer Drugs Market

Cervical Cancer Drugs Market Trends And Outlook
Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged
between 30 and 45. Cervical cancer often shows no symptoms in early stages. However, the
death rate of cervical cancer can be significantly reduced with use of Pap test (Papanicolaou
test): a screening procedure which can detect the changes in the cervix before the cancer
develops. There are different types of cervical cancer, out of which two main types are
squamous cell cancer and adenocarcinoma.
Request Sample Copy of Research Report @
Cervical Cancer Drugs Market Drivers
Increasing number of drug approval done by U.S. Food and Drug Administration (FDA) for the
treatment of cervical cancer is expected to drive growth of the cervical cancer drugs market
over the forecast period. For instance, in September 2017, U.S. Food and Drug Administration
(FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the
treatment of multiple types of cancer, which includes cervical, lung, brain, colorectal and
kidney cancer. Mvasi is indicated for use in persistent, recurrent, or metastatic cervical cancer.
In August 2014, U.S. FDA approved Genentech’s Avastin, which is bevacizumab solution for
intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or
metastatic cervical cancer.
Furthermore, increasing funding for cancer research, rising insurance coverage, and increase in
the number of new targeted cancer drugs are expected to support the revenue growth of
cervical cancer drugs market. For instance, National Cancer Institute, in 2015, spent around
US$ 4,480 million on cancer research, which include cervical cancer, lung cancer, colorectal
cancer, liver cancer, breast cancer, leukaemia, ovarian cancer, and uterine cancer. Furthermore,
according to the American Cancer Society, U.S. invested around US$ 87.8 billion in 2014 on
cancer research, in which the major cost accounting for around 44%, was paid by private
insurance companies.
Increasing incidence of cervical cancer among the global population, rise in incidence of HIV in
women, lack of awareness regarding the diagnosis for prevention of invasive cancer is expected
to drive growth of the cervical cancer drugs market. Moreover, American cancer Society, in
March 2018, funded around 22 grants for cervical cancer, which accounted for around US$ 9.3
million. The funding value is offered to a single or group of research, which includes a specific
type of a cancer or area of cancer. For instance, according to Cancer Research UK, 2015 data
findings, around 3,200 new cervical cancer cases were registered in the UK annually from 2013
to 2015.
Moreover, according to the same source, in 2015, cervical cancer accounted for around 2% of
all cancer cases in females in the UK. A joint study conducted on cervical cancer by the
Associated Chambers of Commerce and Industry of India (ASSOCHAM) and National Institute of
Cancer Prevention and Research (NICPR), published in January 2018, reported that India alone
has one fourth of the global burden of cervical cancer, which accounts for 17% of the all
cancer deaths in women aged between 30 and 69 years in India. Moreover, according to the
same source, it is estimated that around 1 in 53 Indian women are expected to be diagnosed by
cervical cancer during their lifetime.
Report includes chapters which deeply display the following deliverable about industry :
• Cervical Cancer Drugs Market Research Objective and Assumption
• Cervical Cancer Drugs Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Cervical Cancer Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Cervical Cancer Drugs Market, By Regions
• Cervical Cancer Drugs Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Cervical Cancer Drugs Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Cervical Cancer Drugs Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Cervical Cancer Drugs Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Cervical Cancer Drugs Market - Regional Analysis
Geographically, cervical cancer drugs market is segmented into North America, Latin America,
Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in
cervical cancer drugs market, owing to increasing incidences of cervical cancer and growing
research and development activities by various healthcare regulatory organizations in these
region. For instance, according to the American Cancer Society’s (ACS) estimates for cervical
cancer in the U.S. for 2018, around 13, 240 new cases of invasive cervical cancer were
diagnosed and around 4,170 women are expected to die from cervical cancer. For instance, in
2013, Cervical Cancer-Free Coalition (CCFC) announced a collaborative research projects with
funds ranging from US$ 5,000-US $10,000 each, which are focused on cervical cancer treatment
in the U.S.
Browse Complete Report For More Information @
Cervical Cancer Drugs Market Competitive Landscape
Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La
Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals,
Inc., Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company,
and Novartis AG. Key players operating in the market are focused on organic growth strategies,
in order to enhance its market share and retain its competence in the market. For instance, in
July 2014, MedImmune: a biologics research and development division of AstraZeneca entered
into a clinical trial collaboration with Advaxis. According to the agreement, both companies
conducted Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s
investigational anti-PD-L1 immune checkpoint inhibitor: MEDI4736, in combination with
Advaxis’ cancer immunotherapy vaccine: ADXS-HPV. These study is conducted to develop
treatment for patients with advanced, recurrent or refractory Human Papillomavirus (HPV)associated cervical cancer.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged between 30 and 45.